Managing IP Products

Browse Magazine

IP Resources

16 April 2009

EU pharma sector enquiry slammed

James Nurton, Cambridge

The European Commission’s pharmaceutical sector enquiry could have “a chilling effect on innovation in Europe” if the preliminary report is carried through into its final version, according to a pharmaceutical company executive

Speaking during the Fordham IP Conference in Cambridge, UK, David Rosenberg of GlaxoSmithKline’s IP department said the preliminary report presented a flawed understanding of the patent system and its relation to pharmaceutical innovation.

The rest of this article is available to subscribers to Managing IP only.

Subscribe today to this product for full access to this article. Alternatively, take a 48-hour free trial giving you access to the current content.

If you are already a subscriber please log in (see top right column) to access the rest of this article.

GSK expands royalty-free licence to HIV drugs 26 Jul 2010
Global awards 2010 01 Jul 2010
Moves 01 Jul 2010
Meet the 50 most influential people in IP 01 Jul 2010
Managing IP Global Awards 2010 24 Jun 2010

Events

Forthcoming conference
Asia-Pacific IP Forum
Sheraton Hotel, Hong Kong
September 1 & 2 2010

Recent web seminar
Listen to archived version
Develop effective patent strategies in Europe

July / August 2010

Meet the 50 most influential people in IP

Managing IP publishes its eighth annual list of the 50 most influential people in IP

Should the .xxx domain be approved?
Yes
No

Disclaimer

Managing Intellectual Property

Navigation Menu

Managing IP Home Page